These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 29248722)

  • 1. Crosstalk between Nrf2 and YAP contributes to maintaining the antioxidant potential and chemoresistance in bladder cancer.
    Ciamporcero E; Daga M; Pizzimenti S; Roetto A; Dianzani C; Compagnone A; Palmieri A; Ullio C; Cangemi L; Pili R; Barrera G
    Free Radic Biol Med; 2018 Feb; 115():447-457. PubMed ID: 29248722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ailanthone inhibits cell growth and migration of cisplatin resistant bladder cancer cells through down-regulation of Nrf2, YAP, and c-Myc expression.
    Daga M; Pizzimenti S; Dianzani C; Cucci MA; Cavalli R; Grattarola M; Ferrara B; Scariot V; Trotta F; Barrera G
    Phytomedicine; 2019 Mar; 56():156-164. PubMed ID: 30668336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ailanthone increases oxidative stress in CDDP-resistant ovarian and bladder cancer cells by inhibiting of Nrf2 and YAP expression through a post-translational mechanism.
    Cucci MA; Grattarola M; Dianzani C; Damia G; Ricci F; Roetto A; Trotta F; Barrera G; Pizzimenti S
    Free Radic Biol Med; 2020 Apr; 150():125-135. PubMed ID: 32101771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-translational down-regulation of Nrf2 and YAP proteins, by targeting deubiquitinases, reduces growth and chemoresistance in pancreatic cancer cells.
    Grattarola M; Cucci MA; Roetto A; Dianzani C; Barrera G; Pizzimenti S
    Free Radic Biol Med; 2021 Oct; 174():202-210. PubMed ID: 34364982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of Chromosome Instability by Activation of Yes-Associated Protein and Forkhead Box M1 in Liver Cancer.
    Weiler SME; Pinna F; Wolf T; Lutz T; Geldiyev A; Sticht C; Knaub M; Thomann S; Bissinger M; Wan S; Rössler S; Becker D; Gretz N; Lang H; Bergmann F; Ustiyan V; Kalin TV; Singer S; Lee JS; Marquardt JU; Schirmacher P; Kalinichenko VV; Breuhahn K
    Gastroenterology; 2017 Jun; 152(8):2037-2051.e22. PubMed ID: 28249813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-translational inhibition of YAP oncogene expression by 4-hydroxynonenal in bladder cancer cells.
    Cucci MA; Compagnone A; Daga M; Grattarola M; Ullio C; Roetto A; Palmieri A; Rosa AC; Argenziano M; Cavalli R; Simile MM; Pascale RM; Dianzani C; Barrera G; Pizzimenti S
    Free Radic Biol Med; 2019 Sep; 141():205-219. PubMed ID: 31207288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A role for YAP/FOXM1/Nrf2 axis in oxidative stress and apoptosis of cataract induced by UVB irradiation.
    Hong Y; Sun Y; Ainiwaer M; Xiao B; Zhang S; Ning L; Zhu X; Ji Y
    FASEB J; 2024 Jul; 38(14):e23832. PubMed ID: 39046354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer.
    Hayden A; Douglas J; Sommerlad M; Andrews L; Gould K; Hussain S; Thomas GJ; Packham G; Crabb SJ
    Urol Oncol; 2014 Aug; 32(6):806-14. PubMed ID: 24837013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced B-Raf-mediated NRF2 gene transcription and HATs-mediated NRF2 protein acetylation contributes to ABCC1-mediated chemoresistance and glutathione-mediated survival in acquired topoisomerase II poison-resistant cancer cells.
    Chen HH; Chang HH; Chang JY; Tang YC; Cheng YC; Lin LM; Cheng SY; Huang CH; Sun MW; Chen CT; Kuo CC
    Free Radic Biol Med; 2017 Dec; 113():505-518. PubMed ID: 29080842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOXM1 is a downstream target of LPA and YAP oncogenic signaling pathways in high grade serous ovarian cancer.
    Fan Q; Cai Q; Xu Y
    Oncotarget; 2015 Sep; 6(29):27688-99. PubMed ID: 26299613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxaliplatin activates the Keap1/Nrf2 antioxidant system conferring protection against the cytotoxicity of anticancer drugs.
    Wang XJ; Li Y; Luo L; Wang H; Chi Z; Xin A; Li X; Wu J; Tang X
    Free Radic Biol Med; 2014 May; 70():68-77. PubMed ID: 24556415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance.
    Cho JM; Manandhar S; Lee HR; Park HM; Kwak MK
    Cancer Lett; 2008 Feb; 260(1-2):96-108. PubMed ID: 18036733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma.
    Lee BS; Park DI; Lee DH; Lee JE; Yeo MK; Park YH; Lim DS; Choi W; Lee DH; Yoo G; Kim HB; Kang D; Moon JY; Jung SS; Kim JO; Cho SY; Park HS; Chung C
    Biochem Biophys Res Commun; 2017 Sep; 491(2):493-499. PubMed ID: 28684311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting an Autocrine Regulatory Loop in Cancer Stem-like Cells Impairs the Progression and Chemotherapy Resistance of Bladder Cancer.
    Wang KJ; Wang C; Dai LH; Yang J; Huang H; Ma XJ; Zhou Z; Yang ZY; Xu WD; Hua MM; Lu X; Zeng SX; Wang HQ; Zhang ZS; Cheng YQ; Liu D; Tian QQ; Sun YH; Xu CL
    Clin Cancer Res; 2019 Feb; 25(3):1070-1086. PubMed ID: 30397177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hippo/YAP signaling pathway is involved in osteosarcoma chemoresistance.
    Wang DY; Wu YN; Huang JQ; Wang W; Xu M; Jia JP; Han G; Mao BB; Bi WZ
    Chin J Cancer; 2016 May; 35():47. PubMed ID: 27206784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage.
    Ciamporcero E; Shen H; Ramakrishnan S; Yu Ku S; Chintala S; Shen L; Adelaiye R; Miles KM; Ullio C; Pizzimenti S; Daga M; Azabdaftari G; Attwood K; Johnson C; Zhang J; Barrera G; Pili R
    Oncogene; 2016 Mar; 35(12):1541-53. PubMed ID: 26119935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABCF2, an Nrf2 target gene, contributes to cisplatin resistance in ovarian cancer cells.
    Bao L; Wu J; Dodson M; Rojo de la Vega EM; Ning Y; Zhang Z; Yao M; Zhang DD; Xu C; Yi X
    Mol Carcinog; 2017 Jun; 56(6):1543-1553. PubMed ID: 28112439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Curcumin promotes KLF5 proteasome degradation through downregulating YAP/TAZ in bladder cancer cells.
    Gao Y; Shi Q; Xu S; Du C; Liang L; Wu K; Wang K; Wang X; Chang LS; He D; Guo P
    Int J Mol Sci; 2014 Aug; 15(9):15173-87. PubMed ID: 25170806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.
    Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y
    Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis.
    Roh JL; Kim EH; Jang H; Shin D
    Redox Biol; 2017 Apr; 11():254-262. PubMed ID: 28012440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.